An Overview of COVID-19 Vaccines: Challenges of the Discovery and Development by the Pharmaceutical Industries

References (58)

1. 1 Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine [DOI]
2. 2 Determinants of disparities between perceived and physiological risk of falling among elderly people: cohort study. [DOI]
3. 3 Pathophysiology, Transmission, Diagnosis, and Treatment of Coronavirus Disease 2019 (COVID-19) [DOI]
4. 4 Thrombotic Thrombocytopenia after ChAdOx1 nCov-19 Vaccination [DOI]
5. 5 Vaccine hesitancy [DOI]
6. 6 The COVID-19 vaccine development landscape [DOI]
7. 7 Covid-19 — Navigating the Uncharted [DOI]
8. 8 Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials [DOI]
9. 9 Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBIBP-CorV: a randomised, double-blind, placebo-controlled, phase 1/2 trial [DOI]
10. 10 Responding to Covid-19 — A Once-in-a-Century Pandemic? [DOI]
11. 11 Delivering the Messenger: Advances in Technologies for Therapeutic mRNA Delivery [DOI]
12. 12 What defines an efficacious COVID-19 vaccine? A review of the challenges assessing the clinical efficacy of vaccines against SARS-CoV-2 [DOI]
13. 13 β-Coronaviruses Use Lysosomes for Egress Instead of the Biosynthetic Secretory Pathway [DOI]
14. 14 Evolution of the COVID-19 vaccine development landscape [DOI]
15. 15 Convalescent plasma in Covid-19: Possible mechanisms of action [DOI]
16. 16 Coronavirus vaccine development: from SARS and MERS to COVID-19 [DOI]
17. 17 BNT162b2 mRNA COVID-19 Vaccine: First Approval [DOI]
18. 18 Autoimmune heparin‐induced thrombocytopenia [DOI]
19. 19 Sputnik V COVID-19 vaccine candidate appears safe and effective [DOI]
20. 20 Convalescent plasma or hyperimmune immunoglobulin for people with COVID-19: a living systematic review [DOI]
21. 21 Three decades of messenger RNA vaccine development [DOI]
22. 22 COVID-19 in Children: Where do we Stand? [DOI]
23. 23 Recent Advances in the Vaccine Development Against Middle East Respiratory Syndrome-Coronavirus [DOI]
24. 24 Non-viral COVID-19 vaccine delivery systems [DOI]
25. 25 Disease X: accelerating the development of medical countermeasures for the next pandemic [DOI]
26. 26 Reserving coronavirus disease 2019 vaccines for global access: cross sectional analysis [DOI]
27. 27 COVID‐19 vaccine‐associated immune thrombosis and thrombocytopenia (VITT): Diagnostic and therapeutic recommendations for a new syndrome [DOI]
28. 28 Coronavirus Disease (COVID-19): Current Status and Prospects for Drug and Vaccine Development [DOI]
29. 29 Development and Characterization of a Severe Acute Respiratory Syndrome–Associated Coronavirus–Neutralizing Human Monoclonal Antibody That Provides Effective Immunoprophylaxis in Mice [DOI]
30. 30 COVID-19 vaccine: where are we now and where should we go? [DOI]
31. 31 Splanchnic Vein Thrombosis: Current Perspectives [DOI]
32. 32 COVID‐19 vaccine research and development: ethical issues [DOI]
33. 33 COVID-19 vaccine development: a pediatric perspective [DOI]
34. 34 Cutaneous Adverse Reactions to COVID-19 Vaccines: Insights from an Immuno-Dermatological Perspective [DOI]
35. 35 Therapy with a Severe Acute Respiratory Syndrome–Associated Coronavirus–Neutralizing Human Monoclonal Antibody Reduces Disease Severity and Viral Burden in Golden Syrian Hamsters [DOI]
36. 36 COVID-19 Vaccine and Myocarditis [DOI]
37. 37 The coronavirus disease (COVID-19) – A supportive approach with selected micronutrients [DOI]
38. 38 SARS (Severe Acute Respiratory Syndrome)
39. 39 Convalescent plasma for covid-19 [DOI]
40. 40 Severe acute respiratory syndrome [DOI]
41. 41 Middle East respiratory syndrome coronavirus: a comprehensive review [DOI]
42. 42 J&J’s one-shot COVID vaccine offers hope for faster protection [DOI]
43. 43 COVID-19 vaccine dilemmas [DOI]
44. 44 The Drug Development Process [DOI]
45. 45 Convalescent plasma treatment for COVID‐19: Tempering expectations with the influenza experience [DOI]
46. 46 Underpromise, overdeliver [DOI]
47. 47 COVID-19 Vaccines as Global Common Goods: An Integrated Approach of Ethical, Economic Policy and Intellectual Property Management [DOI]
48. 48 Science [DOI]
49. 49 How COVID vaccines are being divvied up around the world [DOI]
50. 50 Convalescent plasma is ineffective for covid-19 [DOI]
51. 51 Real-world effectiveness of COVID-19 vaccines: a literature review and meta-analysis [DOI]
52. 52 Association Between 3 Doses of mRNA COVID-19 Vaccine and Symptomatic Infection Caused by the SARS-CoV-2 Omicron and Delta Variants [DOI]
53. 53 New‐onset autoimmune phenomena post‐COVID‐19 vaccination [DOI]
54. 54 Diagnostics for COVID-19: moving from pandemic response to control [DOI]
55. 55 Covid-19: Omicron may be more transmissible than other variants and partly resistant to existing vaccines, scientists fear [DOI]
56. 56 Convalescent plasma or hyperimmune immunoglobulin for people with COVID-19: a living systematic review [DOI]
57. 57 Systematic review of the safety, immunogenicity, and effectiveness of COVID‐19 vaccines in pregnant and lactating individuals and their infants [DOI]
58. 58 Antidoping Concept of Play Clean to Win Clean: Implication of Herbal Supplements uses for Athletes in Competitive Sports [DOI]

Cited by 0

No indexed citations yet.

Related research

• Covid-2019:“A Microbiological Monster” — shares topic coverage
• COVID 19 Disease Caused by Coronavirus 2 (SARS-CoV-2) (Severe Acute Respiratory Syndrome) — shares topic coverage
• Using Ultraviolet A to Check Inanimate Objects for Thorough Cleanliness during COVID-19 Pandemic — shares topic coverage
• The Evaluation of Biochemical Parameters in Positive COVID-19 RealTime PCR Patients: A Retrospective Study — shares topic coverage
• Characteristics of the New Coronavirus Named SARS-CoV-2 Responsible for an Infection Called Coronavirus Disease 2019 (COVID-19) — shares topic coverage